[Pyrazoloacridine is an acridine derivative topoisomerase I/II inhibitor currently undergoing clinical evaluation. It binds to DNA by intercalation. In preclinical testing has shown selectivity for solid tumor cell lines, activity in hypoxic, noncycling, and multidrug-resistant cell lines, and synergy with cisplatin. ( NCI )]
UMLS (NCI) C0280970 - Organic Chemical
- Pharmacologic Substance